Table 3.
Selection of studies that reported diagnostic and prognostic models potentially relevant for clinical practice.
| Sample | Method | Findings/Models | Reference |
| Uterine fibroids | |||
| tissue samples | LC-MS/MS | Leiomyomas/myometrium: 70 metabolites dysregulated; ↓ homocarnosine, haeme, biliverdin, stratification between FH and MED12 subtype |
[67] |
| Endometriosis | |||
| serum | 1H-NMR | ↑ lactate, 2-hydroxybutyrate, succinate, Lys, glcerophosphocholine, citric acid, pyruvate, adipic acid; ↓ Ile, Leu, Arg, Asp, Ala, Glu, creatine; IW/E AUC: 0.99, SEN: 100%, SP: 91.6% |
[69] |
| plasma | LC-MS/MS | ↑ lauroylcarnitine, oleylcarnitine, myristoylcarnitine, long-chain acylcarnitines; ↓ trimethylamine-N-oxide; CP/E: SEN: 81.8%, SP: 88.9%, PPV: 75% |
[77] |
| peritoneal fluid | ESI-MS/MS |
HW/OE (C0/PCae C36:0, PCaa C30:0/PCae C32:2, age) AUC: 0.94, SEN: 82.8%, SP: 94.4% |
[72] |
| endometrial fluid | LC-MS/MS | ↓ sphingolipids, glycerolipids; ↑ mono or polyunsaturated TAG; CW/OE (model of 123 metabolites): SEN: 58.3%, SP: 100% |
[73] |
| eutopic endometrium | LC-MS |
IW/E (PC (18:1/22:6), PC (20:1/14:1), PC (20:3/20:4), PS (20:3/23:1), PA (25:5/22:6)); AUC: 0.87, SEN: 90.5%, SP: 75.0% |
[75] |
| eutopic endometrium | LC-MS |
IW/E (uric acid, hypoxanthine, lysophosphatidylethanolamine); AUC: 0.87, SEN: 66.7%, SP: 90.0% |
[76] |
| Cervical cancer | |||
| plasma | LC-MS |
CR/SD: (Val + Trp) AUC: 0.94, SEN: 87%, SP: 80%; CR + PR/SD: (Trp) AUC: 0.82 |
[78] |
| plasma | LC-MS/MS |
HW/CC: (bilirubin, LysoPC (17:0), n-oleoyl Thr, 12-hydroxydodecanoic acid, tetracosahexaenoic acid); AUC: 0.99, SEN: 98%, SP: 99% |
[79] |
| plasma | LC-MS | phthalic acid, D-maltose, PG (12:0/13:0), LacCer (d18:1/16:0), PC (15:0/16:09); CC before/poor prognosis: AUC: 0.97, SEN: 94%, SP: 87%; CC before/good prognosis: AUC: 0.97, SEN: 92%, SP: 89% |
[80] |
| Endometrial cancer | |||
| plasma | LC-MS/MS |
BD/EC (C16/PCae C40:1, Pro/Tyr, PCaa C42:0/PCae C44:5); AUC: 0.84, SEN: 85.3%, SP: 69.2% MI-/MI+ (SMOH C14:1/SMOH C24:1, PCaa C40:2/PCaa C42:6); AUC: 0.86, SEN: 81.3%, SP: 86.4% LVI-/LVI+ (PCaa C34:4/PCae C38:3, C16:2/PCaa C38:1); AUC: 0.94, SEN: 88.9%, SP: 84.3% |
[81] |
| plasma | LC-MS/MS | EC long/short survival (MetSO, serotonin, spermine, C3-OH, PCaa C36:5, SM C20:2, spermidine, C4:1, lyso PCaa C18:2, lysoPCaa C24:0, Asp, dimethylarginin, hexose, PCae C30:1); AUC: 0.965 | [82] |
| serum | GC-MS |
EC type 1/type 2: ↓ lactic acid, cystine, Ser, malate, Glu, homocysteine; ↑ progesterone; Accuracy: 0.93, SEN: 96%, SP: 86% |
[83] |
| serum | LC-MS/MS |
C/EC (spermine, isovalerate, glycylvaline, gamma-glutamyl-2-aminobutyrate); AUC: 0.92 R/NR (2-oleoylgycerol, TAG 42:2-FA12:0); AUC: 0.90 |
[84] |
| cervico-vaginal fluid | 1H-NMR |
CP/EC (phosphocholine, malate, Asp); Accuracy: 0.78, SEN: 75%, SP: 80% |
[85] |
Legend: AUC, area under the curve; BD, benign diseases; BT, before treatment; CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CP, control patients; CR, patients with complete response to chemotherapy; CW, control women; E, endometriosis, EC, endometrial cancer; FA, fatty acid; IW, infertile women; NR, non-recurrent; OE, ovarian endometriosis; PPV, positive predictive value; PR, patients with partial response to chemotherapy; R, recurrent; MI, myometrial invasion; LVI, lymphovascular invasion; TAG, triacylglycerol; PA, phosphatidic acid; PC, phosphatidylcholine; PS, phosphatidylserine; PCae, PCaa, glycerophospholipids; SD, patients with stable disease; SEN, sensitivity; SP, specificity; SMOH, hydroxysphingomyelin. Only studies that reached a QUADOMICS score (no/not clear ≤60%) were included. All models need further validation.